J&J researchers: Not enough evidence found so far linking COVID-19 vaccine to blood clots

These reports of cerebral venous sinus, thrombosis and thrombosis. Agrippina are similar to reports of thrombin attic events with thrombosis Dapena seen in europe after vaccination with the astrazeneca vaccine. In the european cases, both men and women presented with the blood clots, though they were more frequent in women, the astrazeneca Don johnson johnson vaccines both use an adenovirus factor. These vaccines are different from the Pfizer and Moderna vaccines, which are MRNA based vaccines and to be very clear these types of reactions. Blood clots in combination with low platelets are not being seen with the authorized vaccines from Pfizer and Moderna. I know the information we have presented may be very concerning to americans, especially those who have already received the johnson and johnson vaccine. For people who have received the vaccine more than a month ago, the risk of a blood clot is exceptionally low. For people receive the vaccine meaning recently, meaning within the last few weeks they should be aware of their symptoms and immediately seek medical assistance with any symptoms of concern. But also I want to reiterate to this group. Even in this group, these events are extremely rare symptoms of a cerebral venous sinus, thrombosis or other associated severe blood clot. Might include a severe headache, abdominal pain, leg pain, or shortness of breath, all leading to an emergency department visits. Importantly, we have two other vaccines that are authorized for use in this country. Again, we are not seeing these events with the other two vaccines with Pfizer and Moderna. Jointly CDC and FDA were able to identify these rare events and act quickly to alert health care providers and the public. This demonstrates that the safety systems we have in place are working. We will continue to monitor vaccinations and adverse events across this country. This pause will allow us to accelerate reporting of possible adverse events from healthcare providers across the country and all of you. Yeah.

In a letter published in the New England Journal of Medicine Friday, researchers at Johnson & Johnson say they have yet "to establish a causal relationship" between a handful of unusual blood clot cases and the company's COVID-19 vaccine."We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public," researchers said. The blood clot reports are exceedingly rare �� six cases out of more than 7 million U.S. inoculations with the one-dose vaccine. But the U.S. government on Tuesday recommended a pause in J&J vaccinations, not long after European regulators declared that such clots are a rare but possible risk with the AstraZeneca vaccine, a shot made in a similar way but not yet approved for use in the U.S.At an emergency meeting Wednesday, advisers to the Centers for Disease Control and Prevention wrestled with the fact that the U.S. has enough vaccine alternatives to do without the J&J vaccine for a time, but other countries anxiously awaiting the one-and-done shot may not.Members of the Advisory Committee on Immunization Practices committee said they did not have enough information to make changes in their recommendations, or even to suggest extending a pause in administering the vaccine. One committee member, Dr. Grace Lee, was among those who advocated tabling a vote. She echoed concerns about getting more data to better understand the size of the risk and whether it was greater for any particular group of people."I continue to feel like we're in a race against time and the variants, but we need to (move forward) in the safest possible way," said Lee, of Stanford University.The clots under investigation are highly unusual. They occurred in strange places, in veins that drain blood from the brain, and in people with abnormally low levels of clot-forming platelets. The six cases raised an alarm bell because that number is at least three times more than experts would have expected to see even of more typical brain-drainage clots, said CDC's Dr. Tom Shimabukuro. "What we have here is a picture of clots forming in large vessels where we have low platelets," Shimabukuro explained. "This usually doesn't happen," but it's similar to European reports with the AstraZeneca vaccine.

In a letter published in the Friday, researchers at Johnson & Johnson say they have yet "to establish a causal relationship" between a handful of unusual blood clot cases and the company's COVID-19 vaccine.

"We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public," researchers said.

The blood clot reports are exceedingly rare �� six cases out of more than 7 million U.S. inoculations with the one-dose vaccine. But the U.S. government on Tuesday recommended a pause in J&J vaccinations, not long after European regulators declared that such clots are a rare but possible risk with the AstraZeneca vaccine, a shot made in a similar way but not yet approved for use in the U.S.

At an emergency meeting Wednesday, advisers to the Centers for Disease Control and Prevention wrestled with the fact that the U.S. has enough vaccine alternatives to do without the J&J vaccine for a time, but other countries anxiously awaiting the one-and-done shot may not.

Members of the Advisory Committee on Immunization Practices committee said they did not have enough information to make changes in their recommendations, or even to suggest extending a pause in administering the vaccine.

One committee member, Dr. Grace Lee, was among those who advocated tabling a vote. She echoed concerns about getting more data to better understand the size of the risk and whether it was greater for any particular group of people.

"I continue to feel like we're in a race against time and the variants, but we need to (move forward) in the safest possible way," said Lee, of Stanford University.

The clots under investigation are highly unusual. They occurred in strange places, in veins that drain blood from the brain, and in people with abnormally low levels of clot-forming platelets. The six cases raised an alarm bell because that number is at least three times more than experts would have expected to see even of more typical brain-drainage clots, said CDC's Dr. Tom Shimabukuro.

"What we have here is a picture of clots forming in large vessels where we have low platelets," Shimabukuro explained. "This usually doesn't happen," but it's similar to European reports with the AstraZeneca vaccine.

��������

J&J researchers: Not enough evidence found so far linking COVID-19 vaccine to blood clots

Share

Share

Share

Top Picks

��